CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Analyst Earnings Estimates
NASDAQ:CMMB - Nasdaq - US16385C1045 - ADR - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A 292.66% | N/A 119.42% | N/A 71.83% | |||||
| EBITDA YoY % growth | -19.27M | -10.94M 43.23% | -12.34M -12.80% | -28.47M -130.71% | -25.392M 10.81% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -19.55M | -10.96M 43.94% | -12.37M -12.86% | -28.53M -130.64% | -25.459M 10.76% | N/A 36.76% | N/A -21.42% | N/A -35.17% | N/A 6.57% | N/A -23.65% | N/A 66.94% | N/A 710.52% | N/A 197.92% | N/A 89.94% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -63.20 | N/A | -1.18 | -1.75 -47.88% | N/A 92.99% | N/A -237.50% | N/A 3.70% | N/A -82.05% | N/A 92.96% | N/A -10.00% | N/A 81.82% | N/A 1,500.00% | N/A 200.00% | N/A 61.90% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 -290.00% | -0.01 96.36% | -0.01 96.08% | -0.01 -2.00% | -0.01 87.18% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.042M -5.04% | -4.328M -6.93% | -4.575M -21.42% | -4.852M -30.77% | -5.162M -27.72% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.01 41.18% | -0.01 | 0.00 | -63.40% |
| Q2 2024 Q2Q % growth | -0.26 -749.67% | -0.01 | -0.25 | -1,720.73% |
| Q1 2024 Q2Q % growth | -0.28 65.00% | -0.02 | -0.26 | -1,272.55% |
| Q4 2023 Q2Q % growth | 97.21% | -0.02 | % | |
| Q3 2023 Q2Q % growth | -0.02 51.43% | -0.02 | 0.00 | 16.67% |
| Q2 2023 Q2Q % growth | 94.33% | -0.03 | % | |
| Q1 2023 Q2Q % growth | -0.80 -81.82% | -0.03 | -0.77 | -2,514.38% |
| Q4 2022 Q2Q % growth | -0.73 -65.91% | -0.04 | -0.69 | -1,689.22% |
| Q3 2022 Q2Q % growth | -0.04 86.54% | -0.34 | 0.30 | 89.60% |
| Q2 2022 Q2Q % growth | -0.54 -107.69% | -0.26 | -0.28 | -107.61% |
| Q1 2022 Q2Q % growth | -0.44 -100.00% | -0.25 | -0.19 | -76.07% |
| Q4 2021 Q2Q % growth | -0.44 | -0.11 | -0.33 | -317.47% |
| Q3 2021 Q2Q % growth | -0.26 | -0.15 | -0.11 | -75.79% |
| Q2 2021 Q2Q % growth | -0.26 | -0.12 | -0.14 | -121.65% |
| Q1 2021 Q2Q % growth | -0.22 97.25% | -0.44 | 0.22 | 49.84% |
| Q1 2020 Q2Q % growth | -8.00 85.71% | -1.88 | -6.12 | -326.26% |
| Q4 2019 Q2Q % growth | 31.20 | -2.04 | 33.24 | 1,629.41% |
| Q3 2019 Q2Q % growth | -34.40 | -2.99 | -31.41 | -1,049.75% |
| Q2 2019 Q2Q % growth | -4.00 | -2.69 | -1.31 | -48.54% |
| Q1 2019 Q2Q % growth | -56.00 | -2.61 | -53.39 | -2,044.61% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | -710% |
| Revenue | N/A | N/A | N/A | N/A |